Jayashankar Lakshmi, Hafner Richard
Columbus Technologies, Inc., Contractor to the National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD , USA.
Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD , USA.
Front Immunol. 2016 Dec 16;7:577. doi: 10.3389/fimmu.2016.00577. eCollection 2016.
Tuberculosis (TB) remains a global health threat of alarming proportions, resulting in 1.5 million deaths worldwide. The only available licensed vaccine, Bacillus Calmette-Guérin, does not confer lifelong protection against active TB. To date, development of an effective vaccine against TB has proven to be elusive, and devising newer approaches for improved vaccination outcomes is an essential goal. Insights gained over the last several years have revealed multiple mechanisms of immune manipulation by (Mtb) in infected macrophages and dendritic cells that support disease progression and block development of protective immunity. This review provides an assessment of the known immunoregulatory mechanisms altered by Mtb, and how new interventions may reverse these effects. Examples include blocking of inhibitory immune cell coreceptor checkpoints (e.g., programed death-1). Conversely, immune mechanisms that strengthen immune cell effector functions may be enhanced by interventions, including stimulatory immune cell coreceptors (e.g., OX40). Modification of the activity of key cell "immunometabolism" signaling pathway molecules, including mechanistic target of rapamycin, glycogen synthase kinase-3β, wnt/β-catenin, adenosine monophosophate-activated protein kinase, and sirtuins, related epigenetic changes, and preventing induction of immune regulatory cells (e.g., regulatory T cells, myeloid-derived suppressor cells) are powerful new approaches to improve vaccine responses. Interventions to favorably modulate these components have been studied primarily in oncology to induce efficient antitumor immune responses, often by potentiation of cancer vaccines. These agents include antibodies and a rapidly increasing number of small molecule drug classes that have contributed to the dramatic immune-based advances in treatment of cancer and other diseases. Because immune responses to malignancies and to Mtb share many similar mechanisms, studies to improve TB vaccine responses using interventions based on "immuno-oncology" are needed to guide possible repurposing. Understanding the regulation of immune cell functions appropriated by Mtb to promote the imbalance between protective and pathogenic immune responses may guide the development of innovative drug-based adjunct approaches to substantially enhance the clinical efficacy of TB vaccines.
结核病(TB)仍然是一个规模惊人的全球健康威胁,在全球范围内导致150万人死亡。唯一可用的获批疫苗卡介苗(Bacillus Calmette-Guérin)并不能提供针对活动性结核病的终身保护。迄今为止,开发一种有效的抗结核疫苗已被证明难以实现,设计新方法以改善疫苗接种效果是一个重要目标。过去几年获得的见解揭示了结核分枝杆菌(Mtb)在受感染的巨噬细胞和树突状细胞中进行免疫操纵的多种机制,这些机制支持疾病进展并阻碍保护性免疫的发展。本综述评估了已知的由Mtb改变的免疫调节机制,以及新的干预措施如何逆转这些影响。示例包括阻断抑制性免疫细胞共受体检查点(例如,程序性死亡-1)。相反,增强免疫细胞效应功能的免疫机制可通过干预措施得到增强,包括刺激性免疫细胞共受体(例如,OX40)。修饰关键细胞“免疫代谢”信号通路分子的活性,包括雷帕霉素的作用靶点、糖原合酶激酶-3β、Wnt/β-连环蛋白、腺苷单磷酸激活的蛋白激酶和沉默调节蛋白,相关的表观遗传变化,以及防止免疫调节细胞(例如,调节性T细胞、髓源性抑制细胞)的诱导,是改善疫苗反应的有力新方法。对这些成分进行有利调节的干预措施主要在肿瘤学中进行了研究,以诱导有效的抗肿瘤免疫反应,通常是通过增强癌症疫苗。这些药物包括抗体和数量迅速增加的小分子药物类别,它们促成了基于免疫的癌症和其他疾病治疗的显著进展。由于对恶性肿瘤和Mtb的免疫反应具有许多相似机制,因此需要开展基于“免疫肿瘤学”干预措施来改善结核疫苗反应的研究,以指导可能的重新利用。了解Mtb利用的免疫细胞功能调节以促进保护性和致病性免疫反应之间的失衡,可能会指导开发基于创新药物的辅助方法,以大幅提高结核疫苗的临床疗效。